Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belvarafenib and Cobimetinib in NRAS-mutant Melanoma
NCT07449754Phase 2Recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- Feb 2026
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Belvarafenib in melanoma, sponsored by Hanmi Pharmaceutical. Started Feb 2026; status: recruiting.
02
Drugs
Belvarafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07449754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07449754.